Prognostic factors of prostate cancer mortality in the Finnish randomized screening trial. Neupane S, Steyerberg E, Raitanen J, Talala K, Pylväläinen J, Taari K, Tammela TLJ, Auvinen A. Int J Urol Nov 2017
Summary: In this study we compared the impact of prognostic predictors of prostate cancer death between cases diagnosed in the screening and control arms of a screening trial, as well as between screen-detected and other cases of the Finnish prostate cancer screening trial. We found different effect on the outcome of cases detected through screening as those diagnosed otherwise. A high diagnostic PSA and advanced disease carried a poor prognosis especially among the cases detected outside screening even when lead-time was eliminated.
A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. Assel M, Sjöblom L, Talala K, Kujala P, Taari K, Auvinen A, Vickers A, Visakorpi T, Tammela T, Lilja H. Eur Urol Focus. 2017 Nov 11
Summary: This study assessed if a panel of four kallikrein markers (total, free, and intact prostate-specific antigen [PSA] and human kallikrein-related peptidase 2 [hK2]) improves predictive accuracy for Gleason score ≥7 (high-grade) prostate cancer among men biopsied for elevated PSA in the Finnish section of ERSPC (FinRSPC). We found that Four kallikrein markers and β-microseminoprotein in blood improve discrimination of high-grade prostate cancer at biopsy in men with elevated prostate-specific antigen.
Impact of PSA threshold and screening interval on PC screening -round 2. Saarimäki L, Hugosson J, Tammela TL, Carlsson S, Talala K, Auvinen A. Published in Eur Urol Focus. 2017
Summary: We compared PC detection rate and PC mortality between the Finnish and Swedish centres and estimated the impact of different screening protocols. The small number of deaths among cases that would have been potentially detectable in Finland with the Swedish protocol (or those that would have been missed in Sweden with the Finnish approach) is unlikely to explain the differences in mortality in this long of a follow-up. A prostate-specific antigen threshold of 3 ng/ml versus 4 ng/ml or a screening interval of 2 yr instead of 4 yr is unlikely to explain the larger mortality reduction achieved in Sweden compared with Finland.
Allopurinol and risk of benign prostatic hyperplasia in Finnish population-based cohort. Kukko V, Kaipia A, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ. Accepted to Prostate Cancer and Prostatic Diseases Oct 2017.
Summary: Benign prostatic hyperplasia (BPH) is a common condition, but etiology is partly unclear. We estimated risk of having clinical BPH by use of gout drug in a Finnish population-based cohort of men. Our study does not show any significant evidence between antihyperuricemic medication using and BPH diagnosis or surgery overall. However, in long-term the risk of clinical BPH may be lowered among men using gout medication.